Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Cancer cells ’’commit suicide’’


Catalysts which cause cancer cells to ’’commit suicide’’ have been developed in the laboratory by West Country scientists.

The research groups of Dr Claus Jacob, of Exeter University and Dr Nicholas Gutowski at the Royal Devon and Exeter Hospital, with support from the Peninsula Medical School, are investigating the anti-cancer effects of biocatalysts that mimic the activity of the human selenium enzyme, glutathione peroxidase. Their work opens up a very promising new direction for anti-cancer research, but both stress that any potential treatment for sufferers is still many years away.

Dr Jacob, of the University’’s School of Biological and Chemical Sciences, explained: ’’The catalysts work by initiating reactions inside the cancer cell that cause it to destroy itself. In effect, the cancer commits
suicide. One of the benefits of this approach is that the drugs target only the diseased cells.

The research opens up the possibility in the future of an entirely new way of treating cancer that has two advantages over conventional treatments:

1. The catalysts use the particular makeup of cancer cells for their activity and thus do not work in healthy cells. This means they are far more targeted than conventional drugs and could potentially avoid many of the unpleasant side effects associated with chemotherapy and radiotherapy.

2. Catalysts are not consumed during their activity but are recycled over and over again. This means that only minute quantities of biocatalyst are needed to kill cancer cells making them highly efficient.

Dr Jacob said: ’’Cancer therapy has long been based on highly toxic substances that randomly kill healthy and sick cells alike. This new approach might allow us to single out sick cells and kill them with a catalytic efficiency far superior to conventional radiation or chemotherapy. The experimental results obtained so far have been truly impressive but further evaluation and clinical trials are required to develop this.’’

The compounds have been developed and synthesised at the University’’s School of Biological and Chemical Sciences and tested in cancer cells at the Royal Devon and Exeter Hospital. The work has been partially funded by the Leverhulme Trust. An Exeter based company has already shown an interest in the compounds and the new method. The most active compound tested so far is a multifunctional catalyst that integrates a quinone with a chalcogen redox system in one chemically simple molecule.

Claus Jacob | alfa

More articles from Health and Medicine:

nachricht NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases

nachricht Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Mars' oceans formed early, possibly aided by massive volcanic eruptions

Oceans formed before Tharsis and evolved together, shaping climate history of Mars

A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...

Im Focus: Tiny implants for cells are functional in vivo

For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.

In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...

Im Focus: Locomotion control with photopigments

Researchers from Göttingen University discover additional function of opsins

Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...

Im Focus: Surveying the Arctic: Tracking down carbon particles

Researchers embark on aerial campaign over Northeast Greenland

On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...

Im Focus: Unique Insights into the Antarctic Ice Shelf System

Data collected on ocean-ice interactions in the little-researched regions of the far south

The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

Virtual reality conference comes to Reutlingen

19.03.2018 | Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

International Tinnitus Conference of the Tinnitus Research Initiative in Regensburg

13.03.2018 | Event News

Latest News

Physicists made crystal lattice from polaritons

20.03.2018 | Physics and Astronomy

Mars' oceans formed early, possibly aided by massive volcanic eruptions

20.03.2018 | Physics and Astronomy

Thawing permafrost produces more methane than expected

20.03.2018 | Earth Sciences

Science & Research
Overview of more VideoLinks >>>